Myovant Sciences Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Myovant Sciences stock.
View analyst ratings for Myovant Sciences or view top-rated stocks.

Wall Street analysts have given Myovant Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Myovant Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Myovant Sciences.

Myovant Sciences Ltd. (NYSE:MYOV) posted its quarterly earnings results on Wednesday, July, 28th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.46. The business earned $41.06 million during the quarter, compared to analyst estimates of $61.19 million.
View Myovant Sciences' earnings history.

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MYOV shares have increased by 153.7% and is now trading at $22.07.
View which stocks have been most impacted by COVID-19.

6 equities research analysts have issued 1-year price objectives for Myovant Sciences' shares. Their forecasts range from $18.00 to $32.00. On average, they expect Myovant Sciences' share price to reach $25.60 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts' price targets for Myovant Sciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Myovant Sciences include Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Sarepta Therapeutics (SRPT), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Allakos (ALLK), Perrigo (PRGO), I-Mab (IMAB), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS) and Arvinas (ARVN).
View all of MYOV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bellevue Group AG (5.72%), State Street Corp (2.49%), PFM Health Sciences LP (2.08%), BlackRock Inc. (1.15%), Vanguard Group Inc. (0.84%) and Lord Abbett & CO. LLC (0.58%). Company insiders that own Myovant Sciences stock include Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, Matthew Lang and Sciences Ltd Roivant.
View institutional ownership trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pier Capital LLC, Goldman Sachs Group Inc., PFM Health Sciences LP, FMR LLC, Group One Trading L.P., Bank of New York Mellon Corp, and Blackcrane Capital LLC. Company insiders that have sold Myovant Sciences company stock in the last year include Ferreira Juan Camilo Arjona, Frank Karbe, and Matthew Lang.
View insider buying and selling activity for Myovant Sciences or view top insider-selling stocks.

MYOV stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Millennium Management LLC, Laurion Capital Management LP, Marshall Wace North America L.P., Citigroup Inc., Blueshift Asset Management LLC, and Point72 Asset Management L.P.. Company insiders that have bought Myovant Sciences stock in the last two years include Chemical Co Ltd Sumitomo, and Sciences Ltd Roivant.
View insider buying and selling activity for Myovant Sciences or or view top insider-buying stocks.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYOV stock can currently be purchased for approximately $22.07.

Myovant Sciences has a market capitalization of $2.03 billion and generates $59.32 million in revenue each year. The company earns $-255,130,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

Myovant Sciences employs 407 workers across the globe.

The official website for Myovant Sciences is www.myovant.com.

Myovant Sciences is headquartered at 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB.

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 442074003351 or via email at [email protected].